Treatment of cytomegalovirus infections in HIV patients;Le traitement des infections a cytomegalovirus an cours de l'infection a VIH

Presse Medicale

Volumn 25, Issue 39, 1996, Pages 1967-1973

  Breton, G ^a   Cremieux A C ^a  

^a BICHAT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; BENZIMIDAVIR; CIDOFOVIR; CYGALOVIR; FOMIVIRSEN; FOSCARNET; GANCICLOVIR; UNCLASSIFIED DRUG; VALACICLOVIR; VIRUS VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PASSIVE IMMUNIZATION; POLYMERASE CHAIN REACTION; PROPHYLAXIS; REVIEW;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; CYTOMEGALOVIRUS RETINITIS; FOSCARNET; GANCICLOVIR; HUMANS;

EID: 0030474619     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Mintz L, Drew WL, Miner RC et al. Cytomegalovirus infections in homosexual men. Ann Intern Med 1983; 99:326-9.
2. Reichert CM, O'Leary TJ, Levens DL et al. Autopsy pathology in the acquired immune deficiency syndrome. Am J Pathol 1993; 112:357-82.
3. Markham A, Faulds D. Ganciclovir, an update of its therapeutic use in cytomegalovirus infection. Drugs 1994; 48:455-84.
4. Wagstaff A, Bryson HM. Foscarnet, a reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections. Drugs 1994; 48:199-226.
5. Cundy KC, Lee WA et al. In: Program and abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy. 1995, San Francisco, abstr. A130.
6. Biron KK, Davis MG, Stanat CC et al. In: Program and abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy. 1996, New Orleans, abstr. H85.
7. Wang LH, Lyogendran S, Weller S et al. In: Program and abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy. 1996, New Orleans, abstr. H28.
8. Snydman DR, Rubin RH, Werner BG et al. New developments in cytomegalovirus prevention and management. Am J Kidney Dis 1993; 21:217-28.
9. Messori A, Rampazzo R, Scroccaro G et al. Efficacy of hyperimmune anti-CMV immunoglobulins for the prevention of CMV infection in recipients of allogeneic bone marrow transplantation: a meta-analysis. Bone Marrow Transplant 1994; 13:163-7.
10. Plotkin SA, Starr SE, Friedman HM et al. Effect of Towne live virus vaccine on CMV disease after renal transplant. Ann Intern Med 1991; 14:1049-54.
11. Studies of ocular complications of AIDS research group, in collaboration with the AIDS clinical trials group. Mortality in patients with AIDS treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. N Engl J Med 1992; 326:213-20.
12. SOCA. Morbidity and tonic effects associated with ganciclovir or foscarnet therapy in a randomized cytomegalovirus retinitis trial. Arch Intern Med 1995; 155:65-73.
13. SOCA. Antiviral effects of foscarnet and ganciclovir therapy on human immunodeficiency virus p24 antigen inpatients with AIDS and cytomegalovirus retinitis. J Infect Dis 1995; 172:613-21.
14. Jacobson MA, Causey D, Polsky B et al. A dose-ranging study of daily maintenance intraveinous foscarnet therapy for cytomegalovirus retinitis in AIDS. J Infect Dis 1993; 168:444-8.
15. Holland GN, Levinson RD, Jacobson MA et al. Dose-related difference in progression rates of CMV retinopathy during foscarnet maintenance therapy. Am J Ophthalmol 1995; 119:576-86.
16. Jacobson MA, Kramer F, Bassiakos Y et al. Randomized phase I trial of two different combination foscarnet and ganciclovir chronic maintenance therapy regimens for AIDS patients with CMV retinitis: AIDS clinical trial group protocol 151. J Infect Dis 1994; 170:189-93.
17. Engstom RE, Holland GN. Local therapy for cytomegalovirus retinopathy. Am J Ophthalmol 1995; 120:376-85.
18. Diaz-Llopis M, Chipont E, Sanchez S et al. Intravitreal foscarnet for cytomegalovirus retinitis in a patient with AIDS. Am J Ophthalmol 1992; 114:742-7.
19. Hutcherson SL, Anderson KP et al. ICCAC. 1995, S143-H136.
20. Groupe d'étude de l'implant de GCV Chiron. In: Program and abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy. 1995, San Francisco, abstr. 1215.
21. The Oral GCV European and Australian Cooperative Study Group. Intravenous versus oral ganciclovir: European/Australian comparative study of efficacy and safety in the prevention of cytomegalovirus retinitis recurrence in patients with AIDS. AIDS 1995; 9:471-7.
22. Drew WL, David I, Lalezari JP et al. Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. N Engl J Med 1995; 333:615-20.
23. Groupe d'étude du GCV oral. In: Program and abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy. 1994, Orlando, abstr. H29.
24. e Conférence Internationale sur le SIDA. 1996, Vancouver, abstr. B305.
25. Salmon-Ceron D, Vildé JL. In: Program and abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy. 1995, San Francisco, abstr. 1228.
26. Youle MS, Gazzard BG, Johnson MA et al. Effects of high-dose oral acyclovir on herpesvirus disease and survival in patients with advanced HIV disease: a double-blind, placebo-controlled study. AIDS 1994; 8:641-9.
27. Feinberg J, Hopkins J. In: Program and abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy. 1995, San Francisco, abstr. 1214.
28. Spector SA, Mac Kinley G, Drew WL et al. A randomized, double-blind study of the efficacy and safety of oral GCV for the prevention of CMV disease in HIV-infected persons. National Conference on Huma Retrovirus and Related Infections. 1995, Washington, abstr. 2.
29. Brosgart CL, Craig C, Hillman D et al. Programs for clinical research on AIDS (CPCRA). A randomized placebo-controlled trial of the safety and efficacy of oral GCV for prophylaxis of CMV retinal and gastrointestinal mucosal disease in HIV-infected individuals with severe immunodepression. In: Program and abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy. 1995, San Francisco, abstr. LB10.
30. e Conférence Internationale sur le SIDA. 1996, Vancouver, abstr. A394.
31. e Conférence Internationale sur le SIDA. 1996, Vancouver, abstr. B302.
32. e Conférence Internationale sur le SIDA. 1996, Vancouver, abstr. A391.
33. Drew WL, Miner RC, Busch DF et al. Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection. J Infect Dis 1991; 163:716-19.
34. Smith IL, Flores-Aguilar M, Taskituna I et al. In: Program and abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy. 1996, Nouvelle Orléans, abstr. H30.
35. Buhles W, Minor D et al. In: Program and abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy. 1994, Orlando, abstr. H30.
36. Lalezari J, Jaffe H et al. In: Program and abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy. 1995, San Francisco, abstr. LB9.
37. Blanshard C, Benhamou Y, Dohin E et al. Treatment of AIDS-associated gastrointestinal cytomegalovirus infection with foscarnet and ganciclovir: a randomized comparison. J Infect Dis 1995; 172:622-8.
38. Wilcox CM, Straub RF, Schwartz DA et al. Cytomegalovirus esophagitis in AIDS: a prospective evaluation of clinical response to ganciclovir therapy, relapse rate, and long-term outcome. Am J Med 1995; 98:169-76.
39. Mayaud C, Herry I, Parrot A et al. Atteintes respiratoires liées au cytomégalovirus au cours du sida. Lettre de l'Infect. 1995:13-15.